+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Gout Therapeutics Market - Segmented by Drug Class, Application, and Geography - Growth, Trends, and Forecast (2018 - 2023)

  • ID: 4622415
  • Report
  • Region: Global
  • 103 pages
  • Mordor Intelligence
1 of 4


  • AstraZeneca plc
  • Boehringer Ingelheim
  • GlaxoSmithKline plc
  • Horizon Pharma plc
  • Merck & Co. Inc
  • Novartis
  • MORE
Gout Therapeutics Market Overview

The Gout Therapeutics Market is expected to grow, at a CAGR of approximately 15% during the forecast period. The recent years has observed growing acceptance of the drugs owing to their capability to yield powerful anti-inflammatory action, with several others currently undergoing clinical trials which are anticipated to be marketed during the forecast period and are expected to drive the market. Some of the marketed products include Krystexxa, Colcrys, Zyloprim, among others which is the approved by the US FDA for gout. On the basis of regional analysis, North America is among the most lucrative region owing to increased awareness in society, multiple major player’s wide presence with their branded products, increasing use of imaging modalities to diagnose gout in better healthcare facilities.

Increasing Alcohol Consumption and the Associated Risk of Gout to Induce a Surge in the Gout Therapeutics Market

There are several studies conducted in past to relate the lifestyle factors contributing to Gout prevalence. Among them, as per a 2015 publication in the “American Journal of Medicine”, it was reported that there was a significant dose-response relationship between the amount of alcohol consumption and risk of recurrent gout attacks. Similar results were replicated by other studies. As per the National Survey on Drug Use and Health (NSDUH) conducted in 2015, it was found that 86.4 % of people aged 18 or older reported drinking alcohol at some point in their lifetime. 70.1 % reported that they drank in the past year; 56.0 % reported that they drank in the past month. Based on the above-mentioned statistics and considering the association between alcoholism and gout it can be expected that increasing alcohol consumption among the primary factor driving the gout therapeutics market over the forecast period.
Other contributing drivers include rising adoption of biologics, with increased R&D on regenerative medicines and technological advancements in imaging modalities improving the gout understanding and clinical applications.

Side Effects of Gout Therapeutic Drugs to Impede the growth of Gout Therapeutics Market

Colchicine is the most common drug deployed for the treatment of gout. Colchicine-induced myopathy and neuropathy might be more recurrent than formerly recognized, and hence patients undergoing long-term therapy must be supervised continuously. Bone marrow depression has been informed, mainly in cases of severe colchicine intoxication, and intravenous administration of the drug has been associated with acute pancytopenia and in some cases even death. Because of its cytogenic effects and reported association with Down's syndrome, the agent should not be used by pregnant women. In addition, the adverse effects affects the complete treatment procedure which raising multiple other disorders such in 2018, high rates of cardiovascular events were reported from the drug febuxostat. Along with slow awareness, these limitations of gout therapeutics results are expected to hamper the growth of the gout therapeutics market.
Another limitation considered under the scope of the study include high indirect cost associated with gout therapeutics.

Asia-Pacific to Emerge as the Fastest Growing Region for the Gout Therapeutics Market

The Asia Pacific countries are anticipated to witness the fastest growth over the forcasted period for this market with the presence of several high econmically growing countries such as India, China, South Korea, and other South Asian countries. The factors such as diversified patient pool, increasing investment by major players with local manufacturers and hospital chains such as Brii Biosciences launched “bring innovative medicines to chinese patients” in collaboration with several pharma firms globally including Ardea Biosciences (AstraZeneca) for gout, raises the growth opportunities and adoption rate in the emerging markets. Additionally, lifestyle factors such as increasing smoking prevalence & alcohol consumption and stressed lifestyle is likely to boost the incidence of gout over the period, 2018-2023.

Key Developments in the Market
  • May, 2018: National Gout Awareness Day and the American Kidney Fund (AKF) collaborated and secured grant to develop gout education campaign and its connection with kidney disease.
  • Aug, 2017: Ironwood Pharmaceuticals received US Food and Drug Administration (US FDA) approval of DUZALLO (lesinurad and allopurinol), for the patient treatment suffering from Hyperuricemia, an uncontrolled gout.

Reasons to Purchase the Gout Therapeutics Market Report
  • Current and future Gout Therapeutics Market outlook in the developed and emerging markets
  • Analysis of various perspectives of the market with the help of Porter’s five forces analysis
  • The segment that is expected to dominate the market
  • Regions that are expected to witness the fastest growth during the forecast period
  • Identify the latest developments, market shares, and strategies employed by the major market players
  • 3-month analyst support, along with the market estimate sheet (in Excel)
Customization of the Gout Therapeutics Market Report
  • This report can be customized to meet your requirements. Please connect with our representative, who will ensure you to get a report that suits your needs.
Note: Product cover images may vary from those shown
2 of 4


  • AstraZeneca plc
  • Boehringer Ingelheim
  • GlaxoSmithKline plc
  • Horizon Pharma plc
  • Merck & Co. Inc
  • Novartis
  • MORE
1. Introduction
1.1 Market Definition

2. Research Methodology

3. Executive Summary

4. Key Inferences

5. Market Overview
5.1 Current Market Scenario
5.2 Porter's Five Forces Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threat of New Entrants
5.2.4 Threat of Substitute Product and Services
5.2.5 Competitive Rivalry within the Industry

6. Market Dynamics
6.1 Drivers
6.1.1 Rising Adoption of Biologics and Increasing R&D on Regenerative Medicines
6.1.2 Rising Prevalence of Gout with Increasing Alcohol Consumption
6.1.3 Technological Advancements in Imaging Modalities Improved Understanding of Gout
6.2 Restraints
6.2.1 Side Effects of Gout Therapeutic Drugs
6.2.2 High Indirect Costs of Gout Therapeutics
6.3 Opportunities
6.4 Key Challenges

7. Market Segmentation
7.1 By Drug Class
7.1.1 NSAIDs
7.1.2 Corticosteroids
7.1.3 Colchicine
7.1.4 Urate-Lowering Agents
7.2 By Application
7.2.1 Acute Gout
7.2.2 Chronic Gout
7.3 By Geography
7.3.1 North America US Canada Mexico
7.3.2 Europe France Germany UK Italy Spain Rest of Europe
7.3.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
7.3.4 Middle East & Africa GCC South Africa Rest of MEA
7.3.5 South America Brazil Argentina Rest of South America

8. Competitive Landscape
8.1 Mergers & Acquisition Analysis
8.2 Agreements, Collaborations, and Partnerships
8.3 New Products Launches

9. Key Players
9.1 AstraZeneca PLC
9.2 Boehringer Ingelheim
9.2 GlaxoSmithKline PLC
9.4 Horizon Pharma PLC
9.5 Merck & Co. Inc
9.6 Novartis AG
9.7 Regeneron Pharmaceuticals
9.8 Savient Pharmaceuticals
9.9 Takeda Pharmaceutical Company Ltd.
9.10 Teijin Pharma Ltd
* List Not Exhaustive

10. Future of the Market
Note: Product cover images may vary from those shown
3 of 4


4 of 4
  • AstraZeneca plc
  • Boehringer Ingelheim
  • GlaxoSmithKline plc
  • Horizon Pharma plc
  • Merck & Co. Inc
  • Novartis
  • Regeneron Pharmaceuticals
  • Savient Pharmaceuticals
  • Takeda Pharmaceutical Company Ltd.
  • Teijin Pharma Ltd
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4622415